BioQ Pharma has expanded its license and supply agreement with Sandoz, a division of Novartis, under which Sandoz now has the right to exclusively market an additional ready-to-use BioQ Pharma infusion pharmaceutical in the U.S. BioQ Pharma is responsible for developing and supplying the unit-dose infusion pharmaceutical, and Sandoz is responsible for obtaining regulatory approval, marketing and commercializing the product.

“We are pleased to grow our relationship with Sandoz, a leader in the pharmaceutical industry, with the addition of a third infusion product to our previously announced agreement. We believe that the presentation of this infusion pharmaceutical, AS-2, may provide important benefits for patients requiring sedation. Additionally, we believe that BioQ Pharma’s ready-to-use infusion system adds value by helping to lower the total cost of drug delivery,” said Josh Kriesel, president and chief executive officer, BioQ Pharma.